1. refusal to provide written informed consent (either the patient or a legal representative); 2. hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); 3. patients with more than 48 hours of prior study medication use; 4. patients with onset of symptoms longer than 14 days; 5. patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; 6. qtc\>= 480ms; 7. do not resuscitate order or exclusive palliative care; 8. patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); 9. patients with known retinopathy or macular degeneration; 10. patients with history of pancreatitis; 11. patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; 12. breastfeeding women; 13. pregnancy

1. refusal to provide written informed consent (either the patient or a legal representative); 2. hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); 3. patients with more than 48 hours of prior study medication use; 4. patients with onset of symptoms longer than 14 days; 5. patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; 6. qtc\>= 480ms; 7. do not resuscitate order or exclusive palliative care; 8. patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); 9. patients with known retinopathy or macular degeneration; 10. patients with history of pancreatitis; 11. patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; 12. breastfeeding women; 13. pregnancy

refusal to provide written informed consent (either the patient or a legal representative); hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); patients with more than 48 hours of prior study medication use; patients with onset of symptoms longer than 14 days; patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; qtc>= 480ms; do not resuscitate order or exclusive palliative care; patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); patients with known retinopathy or macular degeneration; patients with history of pancreatitis; patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; breastfeeding women; pregnancy

refusal to provide written informed consent (either the patient or a legal representative); hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); patients with more than 48 hours of prior study medication use; patients with onset of symptoms longer than 14 days; patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; qtc>= 480ms; do not resuscitate order or exclusive palliative care; patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); patients with known retinopathy or macular degeneration; patients with history of pancreatitis; patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; breastfeeding women; pregnancy

1. refusal to provide written informed consent (either the patient or a legal representative); 2. hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); 3. patients with more than 48 hours of prior study medication use; 4. patients with onset of symptoms longer than 14 days; 5. patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; 6. qtc>= 480ms; 7. do not resuscitate order or exclusive palliative care; 8. patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); 9. patients with known retinopathy or macular degeneration; 10. patients with history of pancreatitis; 11. patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; 12. breastfeeding women; 13. pregnancy

1. refusal to provide written informed consent (either the patient or a legal representative); 2. hypersensitivity to any of the drugs used in the study (azithromycin or hydroxychloroquine); 3. patients with more than 48 hours of prior study medication use; 4. patients with onset of symptoms longer than 14 days; 5. patients with long qt syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (icd).; 6. qtc>= 480ms; 7. do not resuscitate order or exclusive palliative care; 8. patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -alt and aspartate aminotransferase - ast); 9. patients with known retinopathy or macular degeneration; 10. patients with history of pancreatitis; 11. patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine; 12. breastfeeding women; 13. pregnancy